Bo Jesper Hansen

Bo Jesper Hansen has extensive experience from orphan drug research and development, international marketing, and business development, amongst all from being CEO of Swedish Orphan Int’l from 1998-2010. Bo Jesper Hansen is and has previously been chairman and member of the board of directors in a number of biotech and pharma companies, including executive chairman of Swedish Orphan Biovitrum AB (publ), Topotarget A/S (publ), Karolinska Development AB (publ), and chairman of Ablynx NV (publ).

He is Chairman at Karo Pharma AB, Innoventa Medica ApS, Laborie Inc., and Vice-chairman of Orphazyme ApS.

Dr. Bo Jesper Hansen holds a M.D. and Ph.D. from University of Copenhagen, Denmark.